<!DOCTYPE html>
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>fedlex-data-admin-ch-eli-cc-2020-438-20230101-en-docx-1</title>
</head>
<body><div id="lawcontent">
<div id="preface">
<!--818.101.24--><p class="srnummer ">818.101.24</p>
<p class=" man-font-style-italic ">English is not an official language of the Swiss Confederation. This translation is provided for information purposes only, has no legal force and may not be relied on in legal proceedings.</p>
<h1 class="erlasstitel botschafttitel ">Ordinance 3<br>on Measures to Combat the <br>Coronavirus (COVID-19)</h1>
<h2 class="erlasskurztitel ">(COVID-19 Ordinance 3)</h2>
<p>of 19 June 2020 (Status as of 1 January 2023)</p>
</div>
<div id="preamble">
<p>The Swiss Federal Council,</p>
<p class=" man-text-align-left ">based on Articles 3, 4, 5 letters a and b and 8 of the COVID-19 Act of <br>25 September 2020<sup><a href="#fn-d6e27" id="fnbck-d6e27">1</a></sup>, <br>on Article 63 paragraph 3 of the Therapeutic Products Act of 15 December 2000<sup><a href="#fn-d6e37" id="fnbck-d6e37">2</a></sup>,<br>and on Article 41 paragraph 1 of the Epidemics Act of 28 September 2012<sup><sup><a href="#fn-d6e49" id="fnbck-d6e49">3</a></sup></sup> <br>(EpidA),<sup><a href="#fn-d6e59" id="fnbck-d6e59">4</a></sup></p>
<p>ordains:</p>
<div class="footnotes">
<p id="fn-d6e27"><sup><a href="#fnbck-d6e27">1</a></sup>  <a href="https://fedlex.data.admin.ch/eli/cc/2020/711" target="_blank">SR <b>818.102</b></a></p>
<p id="fn-d6e37"><sup><a href="#fnbck-d6e37">2</a></sup>  <a href="https://fedlex.data.admin.ch/eli/cc/2001/422" target="_blank">SR <b>812.21</b></a></p>
<p id="fn-d6e49"><sup><a href="#fnbck-d6e49">3</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2015/297" target="_blank">SR <b>818.101</b></a></p>
<p id="fn-d6e59"><sup><a href="#fnbck-d6e59">4</a></sup> Amended by No I of the O of 19 March 2021 (Employees at High Risk - Extension), in force from 1 April 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/167" target="_blank">AS <b>2021</b> 167</a>).</p>
</div>
</div>
<main id="maintext"><section id="chap_1"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#chap_1">Chapter 1 General Provisions</a>
</h1>
<div class="collapseable"> <article id="art_1"><a name="a1"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_1"><b>Art. 1</b><b></b> <b></b>Subject matter and purpose</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> This Ordinance orders measures applicable to the population, organisations and institutions and the cantons to combat the coronavirus (COVID-19).</p>
<p><sup>2</sup> The measures serve to ensure Switzerland’s capacities to manage the epidemic, in particular to maintain the provision of the population with adequate care and a sufficient supply of essential medical goods.</p>
</div></article><article id="art_2"><a name="a2"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_2"><b>Art. 2</b> Responsibility of the cantons</a>
</h6>
<div class="collapseable"> <p>Unless this Ordinance provides otherwise, the cantons shall retain their responsibilities.</p>
</div></article>
</div></section><section id="chap_2"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#chap_2">Chapter 2  <br>Maintenance of Capacities to provide Healthcare</a>
</h1>
<div class="collapseable">
<section id="chap_2/sec_1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#chap_2/sec_1">Section 1 Principle</a>
</h2>
<div class="collapseable"> <article id="art_3"><a name="a3"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_3"><b>Art. 3</b></a>
</h6>
<div class="collapseable">
<p><sup>1</sup> In order to maintain Switzerland’s capacities to manage the COVID-19 epidemic and in particular to guarantee the provision of the population with adequate care and a sufficient supply of essential medical products, the following measures in particular must be taken: </p>
<dl>
<dt>a.  </dt>
<dd>measures to restrict the entry of persons from high-risk countries and regions and the import and export of goods;</dd>
<dt>b. </dt>
<dd>measures to guarantee the provision of essential medical goods.</dd>
</dl>
<p><sup>2</sup> High-risk countries or regions are countries or regions in which the coronavirus Sars-CoV-2 has been detected and in which:</p>
<dl>
<dt>a. </dt>
<dd>there is an increased risk of infection; or</dd>
<dt>b. </dt>
<dd>a variant of the virus is widespread that carries a higher risk of infection or causes a more severe form of the disease in comparison with the variant of the virus that is prevalent in the Schengen area.<sup><a href="#fn-d6e133" id="fnbck-d6e133">5</a></sup>
</dd>
</dl>
<p><sup>3</sup> The lists of high-risk countries and regions is published in Annex 1.<sup><a href="#fn-d6e145" id="fnbck-d6e145">6</a></sup></p>
<div class="footnotes">
<p id="fn-d6e133"><sup><a href="#fnbck-d6e133">5</a></sup> Amended by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021, in force since 26 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/380" target="_blank">AS <b>2021</b> 380</a>).</p>
<p id="fn-d6e145"><sup><a href="#fnbck-d6e145">6</a></sup> Inserted by Annex 3 of the COVID-19 Ordinance on International Travel Measures of  23 June 2021, in force since 26 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/380" target="_blank">AS <b>2021</b> 380</a>).</p>
</div>
</div></article>
</div></section><section id="chap_2/sec_2"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#chap_2/sec_2">Section 2 <br>Restrictions on Border Crossings and the Admission of Foreign Nationals</a>
</h2>
<div class="collapseable">
<article id="art_4"><a name="a4"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_4"><b>Art. 4</b></a><sup><a href="#fn-d6e162" id="fnbck-d6e162">7</a></sup><a href="#art_4"> Border crossings and controls</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> The following persons shall be refused entry for a period of stay of up to three months that does not require a permit and does not involve gainful employment (Art. 10 of the Foreign Nationals and Integration Act of 16 December 2005<sup><a href="#fn-d6e178" id="fnbck-d6e178">8</a></sup> (FNIA):</p>
<dl>
<dt>a.</dt>
<dd>foreign nationals who wish to enter Switzerland from a high-risk country or from a high-risk region and who do not fall within the scope of the Agreement of 21 June 1999<sup><a href="#fn-d6e191" id="fnbck-d6e191">9</a></sup> between the European Community and its Member States, of the one part, and the Swiss Confederation, of the other part, on the Free Movement of Persons (AFMP) or of the Convention of 4 January 1960<sup><a href="#fn-d6e199" id="fnbck-d6e199">10</a></sup> establishing the European Free Trade Association (EFTA Convention);</dd>
<dt>b. and c.<sup><a href="#fn-d6e210" id="fnbck-d6e210">11</a></sup> </dt>
<dd>... .<sup><a href="#fn-d6e222" id="fnbck-d6e222">12</a></sup>
</dd>
</dl>
<p><sup>2</sup> The following persons are exempt from this ban on entry:</p>
<dl>
<dt>a.<sup><a href="#fn-d6e238" id="fnbck-d6e238">13</a></sup> persons who prove that they have been vaccinated against Sars-CoV-2; the persons who are regarded as having been vaccinated, the period for which the vaccination is valid, and the accepted forms of proof are regulated in Annex 1<i>a </i>number 1;</dt>
<dd class="clearfix"></dd>
<dt>a<sup>bis</sup>.<sup><a href="#fn-d6e255" id="fnbck-d6e255">14</a></sup> </dt>
<dd>persons who prove that they have been infected with Sars-CoV-2 and have recovered; the period for which exemption is valid and the accepted forms of proof are regulated in Annex 1<i>a</i> number 2; </dd>
<dt>b. </dt>
<dd>persons who provide credible evidence that they are in a situation of special necessity;</dd>
<dt>c.<sup><a href="#fn-d6e275" id="fnbck-d6e275">15</a></sup> </dt>
<dd>persons under the age of 18.<sup><a href="#fn-d6e287" id="fnbck-d6e287">16</a></sup> </dd>
</dl>
<p><sup>2bis</sup> ...<sup><a href="#fn-d6e300" id="fnbck-d6e300">17</a></sup></p>
<p><sup>2ter</sup> The exemptions under paragraph 2 letters a, a<sup>bis</sup> and c do not apply to persons who wish to enter Switzerland from a country or region listed in Annex 1 number 2.<sup><a href="#fn-d6e319" id="fnbck-d6e319">18</a></sup> </p>
<p><sup>2quater</sup> The State Secretariat for Migration (SEM) shall issue the required directives on exceptions to the ban on entry.<sup><a href="#fn-d6e337" id="fnbck-d6e337">19</a></sup></p>
<p><sup>3</sup> Decisions taken by the competent authorities may be enforced immediately. Article 65 of the FNIA applies <i>mutatis mutandis</i>. An appeal may be filed against the SEM decision within 30 days of notification. The appeal does not have suspensive effect.</p>
<p><sup>4</sup> The criminal provisions of Article 115 FNIA apply <i>mutatis mutandis</i>. In the event of any violation of the provision on entry, a ban on entry may also be imposed.</p>
<div class="footnotes">
<p id="fn-d6e162"><sup><a href="#fnbck-d6e162">7</a></sup> Amended by No I of the O of 24 June 2020 (Relaxation of Measures relating to Borders, Entry and Admission for Residence and Employment), in force since 6 July 2020  (<a href="https://fedlex.data.admin.ch/eli/oc/2020/480" target="_blank">AS <b>2020</b> 2611</a>).</p>
<p id="fn-d6e178"><sup><a href="#fnbck-d6e178">8</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2007/758" target="_blank">SR <b>142.20</b></a></p>
<p id="fn-d6e191"><sup><a href="#fnbck-d6e191">9</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2002/243" target="_blank">SR <b>0.142.112.681</b></a></p>
<p id="fn-d6e199"><sup><a href="#fnbck-d6e199">10</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/1960/590_635_621" target="_blank">SR <b>0.632.31</b></a></p>
<p id="fn-d6e210"><sup><a href="#fnbck-d6e210">11</a></sup> Repealed by Annex 2 No 2 of the COVID-19 Ordinance on International Travel Measures of 27 Jan. 2021, with effect from 8 Feb. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/61" target="_blank">AS <b>2021</b> 61</a>).</p>
<p id="fn-d6e222"><sup><a href="#fnbck-d6e222">12</a></sup> Amended by No I of the O of 21 Dec. 2020, in force since 21 Dec. 2020 at 1pm  (<a href="https://fedlex.data.admin.ch/eli/oc/2020/1046" target="_blank">AS <b>2020</b> 6395</a>).</p>
<p id="fn-d6e238"><sup><a href="#fnbck-d6e238">13</a></sup> Amended by No I of the O of 18 March 2022, in force since 21 March 2022  (<a href="https://fedlex.data.admin.ch/eli/oc/2022/182" target="_blank">AS <b>2022</b> 182</a>).</p>
<p id="fn-d6e255"><sup><a href="#fnbck-d6e255">14</a></sup> Inserted by No I of the O of 18 March 2022, in force since 21 March 2022  (<a href="https://fedlex.data.admin.ch/eli/oc/2022/182" target="_blank">AS <b>2022</b> 182</a>).</p>
<p id="fn-d6e275"><sup><a href="#fnbck-d6e275">15</a></sup> Inserted by No I of the O of 18 March 2022, in force since 21 March 2022  (<a href="https://fedlex.data.admin.ch/eli/oc/2022/182" target="_blank">AS <b>2022</b> 182</a>).</p>
<p id="fn-d6e287"><sup><a href="#fnbck-d6e287">16</a></sup> Amended by Annex 3 of the COVID-19 Ordinance on International Travel Measures of  23 June 2021, in force since 26 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/380" target="_blank">AS <b>2021</b> 380</a>).</p>
<p id="fn-d6e300"><sup><a href="#fnbck-d6e300">17</a></sup> Inserted by Annex 3 of the COVID-19 Ordinance on International Travel Measures of  23 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/380" target="_blank">AS <b>2021</b> 380</a>). Repealed by No I of the O of 18 March 2022, with effect from 21 March 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/182" target="_blank">AS <b>2022</b> 182</a>).</p>
<p id="fn-d6e319"><sup><a href="#fnbck-d6e319">18</a></sup> Inserted by Annex 3 of the COVID-19 Ordinance on International Travel Measures of  23 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/380" target="_blank">AS <b>2021</b> 380</a>). Amended by No I of the O of 18 March 2022, in force since 21 March 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/182" target="_blank">AS <b>2022</b> 182</a>).</p>
<p id="fn-d6e337"><sup><a href="#fnbck-d6e337">19</a></sup> Inserted by Annex 3 of the COVID-19 Ordinance on International Travel Measures of  23 June 2021, in force since 26 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/380" target="_blank">AS <b>2021</b> 380</a>).</p>
</div>
</div></article><article id="art_5"><a name="a5"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_5"><b>Art. 5</b></a><sup><a href="#fn-d6e359" id="fnbck-d6e359">20</a></sup><a href="#art_5"><i></i> <i></i>Updating the annexes</a>
</h6>
<div class="collapseable"> <p>The Federal Department of Justice and Police (FDJP) shall update Annexes 1 and 1<i>a</i> continuously in consultation with the Federal Department of Home Affairs (FDHA) and the Federal Department of Foreign Affairs (FDFA).</p>
<div class="footnotes"><p id="fn-d6e359"><sup><a href="#fnbck-d6e359">20</a></sup> Amended by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021, in force since 26 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/380" target="_blank">AS <b>2021</b> 380</a>).</p></div>
</div></article><article id="art_6"><a name="a6"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_6"><b>Art. 6</b> and <b>7</b></a><sup><a href="#fn-d6e384" id="fnbck-d6e384">21</a></sup>
</h6>
<div class="collapseable"><div class="footnotes"><p id="fn-d6e384"><sup><a href="#fnbck-d6e384">21</a></sup> Repealed by No I of the O of 24 June 2020 (Relaxation of Measures relating to Borders, Entry and Admission for Residence and Employment), with effect from 6 July 2020  (<a href="https://fedlex.data.admin.ch/eli/oc/2020/480" target="_blank">AS <b>2020</b> 2611</a>).</p></div></div></article><article id="art_8"><a name="a8"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_8"><b>Art. 8</b></a><sup><a href="#fn-d6e398" id="fnbck-d6e398">22</a></sup>
</h6>
<div class="collapseable"><div class="footnotes"><p id="fn-d6e398"><sup><a href="#fnbck-d6e398">22</a></sup> Repealed by Art. 6 No 1 of the COVID-19 Ordinance on International Travel Measures of 2 July 2020, with effect from 6 July 2020 (<a href="https://fedlex.data.admin.ch/eli/oc/2020/496" target="_blank">AS <b>2020</b> 2737</a>).</p></div></div></article><article id="art_9"><a name="a9"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_9"><b>Art. 9</b> Provisions on cross-border movements of persons and goods</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> The FDJP in consultation with the FDHA, the Federal Department of the Environment, Transport, Energy and Communications (DETEC), the FDF and the FDFA shall decide on restrictions on air passenger services from high-risk countries or regions.</p>
<p><sup>2</sup> It may in particular suspend passenger movements for certain flights, close individual airfields with international borders to passenger movements from high-risk countries or regions or prohibit movements of persons to Switzerland from high-risk countries or regions entirely.</p>
<p><sup>3</sup> Restrictions on cross-border movements of persons are set out in Annex 2.</p>
</div></article><article id="art_10"><a name="a10"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_10"><b>Art. 10</b></a><sup><a href="#fn-d6e428" id="fnbck-d6e428">23</a></sup><a href="#art_10"> Granting of visas</a>
</h6>
<div class="collapseable"> <p>Foreign nationals who wish to enter Switzerland from a high-risk country or from a high-risk region and who do not fall within the scope of the AFMP<sup><a href="#fn-d6e443" id="fnbck-d6e443">24</a></sup> or the EFTA Convention<sup><a href="#fn-d6e451" id="fnbck-d6e451">25</a></sup> shall not be granted a Schengen visa for periods of stay of up to three months that do not require a permit and do not involve gainful employment. Exempted from the foregoing are applications from persons under Article 4 paragraph 2.</p>
<div class="footnotes">
<p id="fn-d6e428"><sup><a href="#fnbck-d6e428">23</a></sup> Amended by No I of the O of 18 March 2022, in force since 21 March 2022  (<a href="https://fedlex.data.admin.ch/eli/oc/2022/182" target="_blank">AS <b>2022</b> 182</a>).</p>
<p id="fn-d6e443"><sup><a href="#fnbck-d6e443">24</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2002/243" target="_blank">SR <b>0.142.112.681</b></a></p>
<p id="fn-d6e451"><sup><a href="#fnbck-d6e451">25</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/1960/590_635_621" target="_blank">SR <b>0.632.31</b></a></p>
</div>
</div></article><article id="art_10_a"><a name="a10a"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_10_a"><b>Art. 10</b><i>a</i></a><sup><a href="#fn-d6e463" id="fnbck-d6e463">26</a></sup><a href="#art_10_a"> Extension of deadlines</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> Foreign nationals who have been prevented from acting within the deadlines laid down in Articles 47 or<i> </i>61 FNIA<sup><a href="#fn-d6e481" id="fnbck-d6e481">27</a></sup> because of measures in connection with the coronavirus may carry out the act required at any time while this Ordinance remains in force.</p>
<p><sup>2</sup> By carrying out the required act, they shall achieve the position that would have been achieved had they acted within the prescribed deadline.</p>
<p><sup>3</sup> If the deadlines under Articles 59<i>b</i> or 102<i>a</i> FNIA for updating biometric data in order to obtain or extend a permit cannot be met because of the coronavirus, the permit may still be issued or extended at any time while this Ordinance remains in force.</p>
<div class="footnotes">
<p id="fn-d6e463"><sup><a href="#fnbck-d6e463">26</a></sup> Inserted by No I of the O of 24 June 2020 (Relaxation of Measures relating to Borders, Entry and Admission for Residence and Employment), in force since 6 July 2020  (<a href="https://fedlex.data.admin.ch/eli/oc/2020/480" target="_blank">AS <b>2020</b> 2611</a>).</p>
<p id="fn-d6e481"><sup><a href="#fnbck-d6e481">27</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2007/758" target="_blank">SR <b>142.20</b></a></p>
</div>
</div></article>
</div></section><section id="chap_2/sec_3"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#chap_2/sec_3">Section 3 Provision of Essential Medical Goods</a>
</h2>
<div class="collapseable"> <article id="art_11"><a name="a11"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_11"><b>Art. 11</b>  Definition</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> Medicinal products, medical devices and protective equipment (essential medical goods) that are important and urgently needed to prevent and combat the coronavirus (COVID-19) are the goods listed in Annex 4.</p>
<p><sup>2</sup> The Federal Department of Home Affairs (FDHA) is responsible for the list and shall update the same regularly in consultation with the Interdepartmental Working Group on Medical Goods in accordance with Article 12 and the Spiez Laboratory.<sup><a href="#fn-d6e515" id="fnbck-d6e515">28</a></sup></p>
<p><sup>3</sup> The Federal Office of Public Health (FOPH) shall define the goods that need to be procured and how they should be used. Based on these terms of reference, the FOPH shall determine the quantities required in consultation with the Interdepartmental Working Group on Medical Goods.<sup><a href="#fn-d6e527" id="fnbck-d6e527">29</a></sup></p>
<div class="footnotes">
<p id="fn-d6e515"><sup><a href="#fnbck-d6e515">28</a></sup> Amended by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests), in force since  21 Dec. 2020 (<a href="https://fedlex.data.admin.ch/eli/oc/2020/977" target="_blank">AS <b>2020</b> 5801</a>).</p>
<p id="fn-d6e527"><sup><a href="#fnbck-d6e527">29</a></sup> Amended by No I of the O of 21 Dec. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p>
</div>
</div></article><article id="art_12"><a name="a12"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_12"><b>Art. 12</b> Interdepartmental Working Group on Medical Goods</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> The Interdepartmental Working Group on Medical Goods shall comprise as a minimum representatives from the following federal agencies:</p>
<dl>
<dt>a. </dt>
<dd>the FOPH;</dd>
<dt>b. </dt>
<dd>the Therapeutic Products Division of the Federal Office for National Economic Supply;</dd>
<dt>c.  </dt>
<dd>the Swiss Agency for Therapeutic Products (Swissmedic);</dd>
<dt>d. </dt>
<dd>the National Emergency Operations Centre (NEOC);</dd>
<dt>e. </dt>
<dd>the Medical Services Coordination Committee (SANKO) for Resources Management at Federal Level (ResMaB);</dd>
<dt>f. </dt>
<dd>the Armed Forces Pharmacy;</dd>
<dt>g. </dt>
<dd>the Coordinated Medical Services (CMS).</dd>
</dl>
<p><sup>2</sup> The CMS delegate shall chair the working group.<sup><a href="#fn-d6e571" id="fnbck-d6e571">30</a></sup></p>
<div class="footnotes"><p id="fn-d6e571"><sup><a href="#fnbck-d6e571">30</a></sup> Amended by No II 4 of the O of 23 Sept. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/570" target="_blank">AS <b>2022</b> 570</a>).</p></div>
</div></article><article id="art_13"><a name="a13"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_13"><b>Art. 13</b>  Duty to report</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> The cantons are obliged on request to report to the CMS on the current stocks of essential medical goods in their healthcare facilities.</p>
<p><sup>2</sup> Laboratories and manufacturers and distributors of in vitro diagnostics (COVID-19 tests) are obliged to report regularly to the FOPH on their current stocks of such tests when requested to do so.<sup><a href="#fn-d6e593" id="fnbck-d6e593">31</a></sup></p>
<p><sup>3</sup> The CMS may request details of stocks from companies that store essential medical goods.</p>
<div class="footnotes"><p id="fn-d6e593"><sup><a href="#fnbck-d6e593">31</a></sup> Amended by No I of the O of 21 Dec. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div>
</div></article><article id="art_14"><a name="a14"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_14"><b>Art. 14</b>  Procurement of essential medical goods</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> In order to support the provision of essential medical goods to the cantons and their healthcare facilities, charitable organisations (for example Swiss Red Cross) and third parties (for example laboratories, pharmacies), essential medical goods may be procured if requirements cannot be covered through the normal procurement channels.</p>
<p><sup>2</sup> The essential medical goods that are required shall be determined on the basis of the data transmitted in accordance with Article 13.</p>
<p><sup>3</sup> The Armed Forces Pharmacy is responsible for procuring essential medical goods under paragraph 1 on behalf of the FOPH.</p>
<p><sup>4</sup> The responsible authorities may delegate the procurement of essential medical goods to third parties.</p>
<p><sup>5</sup> When procuring essential medical goods, the Armed Forces Pharmacy may take calculated risks and diverge from the provisions of existing directives and the Financial Budget Act of 7 October 2005<sup><a href="#fn-d6e627" id="fnbck-d6e627">32</a></sup> in relation to risks, such as prepayment without security or currency hedging.</p>
<p><sup>6</sup> The Armed Forces Pharmacy manages the procured essential medical goods as instructed by the Interdepartmental Working Group on Medical Goods.</p>
<div class="footnotes"><p id="fn-d6e627"><sup><a href="#fnbck-d6e627">32</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2006/227" target="_blank">SR <b>611.0</b></a></p></div>
</div></article><article id="art_15"><a name="a15"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_15"><b>Art. 15</b><i> </i><i></i> <i></i>Allocation of essential medical goods</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> The cantons shall submit requests for allocation to the ResMaB as required.<sup><a href="#fn-d6e652" id="fnbck-d6e652">33</a></sup></p>
<p><sup>2</sup> Allocation shall be made continuously based on the supply situation and the current number of cases in each canton.</p>
<p><sup>3</sup> The CMS in consultation with Interdepartmental Working Group on Medical Goods may allocate essential medical goods to the cantons, to charitable organisations and to third parties.</p>
<p><sup>4</sup> …<sup><a href="#fn-d6e670" id="fnbck-d6e670">34</a></sup></p>
<div class="footnotes">
<p id="fn-d6e652"><sup><a href="#fnbck-d6e652">33</a></sup> Amended by No I of the O of 12 May 2021, in force since 17 May 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/274" target="_blank">AS <b>2021</b> 274</a>).</p>
<p id="fn-d6e670"><sup><a href="#fnbck-d6e670">34</a></sup> Repealed by No I of the O of 21 Dec. 2022, with effect from 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p>
</div>
</div></article><article id="art_16"><a name="a16"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_16"><b>Art. 16</b>  Delivery and distribution of essential medical goods</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> The Confederation or the third parties that it instructs shall ensure the delivery of the essential medical goods procured under Article 14 to a distribution centre for each canton. In exceptional cases, the Confederation in consultation with the cantons may supply eligible facilities and organisations directly.</p>
<p><sup>2</sup> The cantons shall designate cantonal distribution centres for goods that are not supplied directly to the recipient, and shall give notice of these to the responsible federal authorities.</p>
<p><sup>3</sup> They shall ensure that essential medical goods that have been delivered are distributed as required and in good time on their territory.</p>
</div></article><article id="art_17"><a name="a17"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_17"><b>Art. 17</b> Direct sales by the Confederation</a>
</h6>
<div class="collapseable"> <p>The Confederation may sell the essential medical goods on the market in return for payment, either itself or through third parties.</p>
</div></article><article id="art_18"><a name="a18"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_18"><b>Art. 18</b><b></b> <b></b>Costs</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> The costs of procuring essential medical goods shall be funded in advance by the Confederation in the cases where it procures the goods.</p>
<p><sup>2</sup> The cantons, charitable organisations and third parties shall notify the Confederation as quickly as possible of the purchasing costs of the essential medical goods supplied to them where the Confederation has assumed responsibility for their procurement in accordance with Article 14 paragraph 1.</p>
<p><sup>3</sup> The Confederation shall bear the costs of delivering the procured essential medical goods to the cantons.</p>
<p><sup>4</sup> The cantons shall bear the costs of distributing these essential medical goods within the canton.</p>
<p><sup>5</sup> If the procured goods become freely available in the market again, the Confederation may sell its stocks at market prices.<sup><a href="#fn-d6e729" id="fnbck-d6e729">35</a></sup></p>
<div class="footnotes"><p id="fn-d6e729"><sup><a href="#fnbck-d6e729">35</a></sup> Inserted by No I of the O of 12 May 2021, in force since 17 May 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/274" target="_blank">AS <b>2021</b> 274</a>).</p></div>
</div></article><article id="art_19"><a name="a19"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_19"><b>Art. 19</b> and <b>20</b></a><sup><a href="#fn-d6e743" id="fnbck-d6e743">36</a></sup>
</h6>
<div class="collapseable"><div class="footnotes"><p id="fn-d6e743"><sup><a href="#fnbck-d6e743">36</a></sup> Repealed by No I of the O of 21 Dec. 2022, with effect from 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div></div></article><article id="art_21"><a name="a21"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_21"><b>Art. 21</b><i></i> <i></i>Exceptions to the requirement of authorisation for medicinal products</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> Medicinal products that are manufactured with active substances under Annex 5 for the treatment of COVID-19 patients may, provided an application for authorisation of a medicinal product containing one of these active substances has been filed, be placed on the market without authorisation pending Swissmedic’s decision on authorisation. When examining applications for authorisation, Swissmedic may permit a relaxation of the relevant requirements for such medicinal products under the law on therapeutic products on the basis of a risk-benefit analysis.</p>
<p><sup>1bis</sup> Medicinal products that are manufactured with active substances under Annex 5<i>a</i> in order to prevent the COVID-19 infection of immunosuppressed persons in whom sufficient immune protection cannot be built up despite vaccination or who cannot be vaccinated may be placed on the market without authorisation after submission of an application for the authorisation of a medicinal product containing any of these active substances until Swissmedic's decision on the authorisation has been taken.<sup><a href="#fn-d6e773" id="fnbck-d6e773">37</a></sup></p>
<p><sup>2</sup> Amendments to the authorisation for a medicinal product authorised in Switzerland containing an active substance under Annex 4 number 1 on the basis of which the medicinal product can be used to treat COVID-19 patients in Switzerland may be made immediately after filing a corresponding amendment application and pending Swissmedic’s decision on authorisation. Swissmedic may, on the basis of a risk-benefit analysis, permit a relaxation of the relevant requirements under the law on therapeutic products for amendments to the authorisation of medicinal products containing an active substance listed in Annex 4 number 1.<sup><a href="#fn-d6e785" id="fnbck-d6e785">38</a></sup></p>
<p><sup>3 </sup>The FDHA shall regularly update the lists in Annexes 5 and 5<i>a</i>.<sup><a href="#fn-d6e799" id="fnbck-d6e799">39</a></sup></p>
<p><sup>4 </sup>Swissmedic may on the basis of a risk-benefit analysis permit changes to the manufacturing process approved within the framework of the authorisation of medicinal products used to prevent and treat COVID-19 in Switzerland. It shall specify criteria according to which the person responsible for technical matters may grant an early market release for medicinal products used to prevent and treat COVID-19 in Switzerland.</p>
<p><sup>5</sup> In derogation from Article 9<i>a</i> paragraph 1 letter c of the Therapeutic Products Act of 15 December 2000, temporary authorisations may be issued even if an authorised equivalent medicinal product that can be used as an alternative is available in Switzerland, provided the authorisations serve to guarantee the supply of medicinal products to prevent and combat the coronavirus in Switzerland.<sup><a href="#fn-d6e816" id="fnbck-d6e816">40</a></sup></p>
<div class="footnotes">
<p id="fn-d6e773"><sup><a href="#fnbck-d6e773">37</a></sup> Inserted by No I of the O of 30 March 2022, in force since 1 April 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/206" target="_blank">AS <b>2022</b> 206</a>).</p>
<p id="fn-d6e785"><sup><a href="#fnbck-d6e785">38</a></sup> Amended by No I of the O of 12 May 2021, in force since 17 May 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/274" target="_blank">AS <b>2021</b> 274</a>).</p>
<p id="fn-d6e799"><sup><a href="#fnbck-d6e799">39</a></sup> Amended by No I of the O of 30 March 2022, in force since 1 April 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/206" target="_blank">AS <b>2022</b> 206</a>).</p>
<p id="fn-d6e816"><sup><a href="#fnbck-d6e816">40</a></sup> Inserted by No I of the O of 27 Oct. 2021, in force since 28 Oct. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/634" target="_blank">AS <b>2021</b> 634</a>).</p>
</div>
</div></article><article id="art_22"><a name="a22"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_22"><b>Art. 22</b><i></i> <i></i>Exceptions to the provisions on the import of medicinal products</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> Following the submission of a authorisation application for a medicinal product containing active substances listed in Annex 5 for the treatment of Covid 19 patients, the applicant may import the medicinal product prior to its authorisation or entrust the import of the medicinal product to a company with a wholesale or import licence.<sup><a href="#fn-d6e838" id="fnbck-d6e838">41</a></sup></p>
<p><sup>1bis</sup> Pharmacists that have pharmaceutical responsibility in a hospital pharmacy may import non-authorised medicinal products with active substances under Annex 5 for the treatment of COVID-19 patients. A company with a wholesale or import licence may be instructed to import such medicinal products.<sup><a href="#fn-d6e850" id="fnbck-d6e850">42</a></sup></p>
<p><sup>2</sup> Notice of each import under paragraph 1<sup>bis</sup> must be given to Swissmedic within 10 days of the arrival of goods.<sup><a href="#fn-d6e859" id="fnbck-d6e859">43</a></sup></p>
<p><sup>2bis</sup> After submitting an application for the authorisation of a medicinal product in accordance with Article 21 paragraph 1<sup>bis</sup>, the applicant may import the medicinal product or instruct a company with a wholesale or import licence to import it before authorisation is granted.<sup><a href="#fn-d6e873" id="fnbck-d6e873">44</a></sup></p>
<p><sup>3</sup> In order to prevent and treat COVID-19 in Switzerland, Swissmedic may allow the temporary placing on the market of a medicinal product as a short-term solution for the temporary non-availability of an identical medicinal product authorised in Switzerland, provided no essentially identical medicinal product is authorised and available in Switzerland.</p>
<p><sup>4</sup> After submitting its application for authorisation for a COVID-19 vaccine and for an operating licence under Article 10 paragraph 1 letter b of the Therapeutic Products Act of 15 December 2000, the applicant may instruct a company with a wholesale or import licence to import the COVID-19 vaccine before its authorisation and to store the vaccine until authorisation is granted. The company instructed must comply with the international rules on good distribution practice in accordance with Annex 4 of the Medicinal Products Licensing Ordinance of 14 November 2018<sup><a href="#fn-d6e888" id="fnbck-d6e888">45</a></sup>.<sup><a href="#fn-d6e896" id="fnbck-d6e896">46</a></sup></p>
<div class="footnotes">
<p id="fn-d6e838"><sup><a href="#fnbck-d6e838">41</a></sup> Inserted by No I of the O of 12 May 2021, in force since 26 April 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/274" target="_blank">AS <b>2021</b> 274</a>).</p>
<p id="fn-d6e850"><sup><a href="#fnbck-d6e850">42</a></sup> Originally para. 1.</p>
<p id="fn-d6e859"><sup><a href="#fnbck-d6e859">43</a></sup> Amended by No I of the O of 12 May 2021, in force since 26 April 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/274" target="_blank">AS <b>2021</b> 274</a>).</p>
<p id="fn-d6e873"><sup><a href="#fnbck-d6e873">44</a></sup> Inserted by No I of the O of 30 March 2022, in force since 1 April 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/206" target="_blank">AS <b>2022</b> 206</a>).</p>
<p id="fn-d6e888"><sup><a href="#fnbck-d6e888">45</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2018/786" target="_blank">SR <b>812.212.1</b></a></p>
<p id="fn-d6e896"><sup><a href="#fnbck-d6e896">46</a></sup> Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests), in force since  21 Dec. 2020 (<a href="https://fedlex.data.admin.ch/eli/oc/2020/977" target="_blank">AS <b>2020</b> 5801</a>).</p>
</div>
</div></article><article id="art_23"><a name="a23"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_23"><b>Art. 23</b><i></i> <i></i>Exceptions for medical devices</a><sup><a href="#fn-d6e912" id="fnbck-d6e912">47</a></sup>
</h6>
<div class="collapseable"> <p><sup>1</sup> In response to an application, Swissmedic may authorise the placing on the market and use of medical devices that have not undergone a conformity assessment procedure in accordance with Article 23 the Medical Devices Ordinance of 1 July 2020<sup><a href="#fn-d6e927" id="fnbck-d6e927">48</a></sup>,<sup><a href="#fn-d6e935" id="fnbck-d6e935">49</a></sup> (MedDO), provided their use for preventing and combating the coronavirus in Switzerland is in the interests of public health or patient safety or health and provided, taking account of their intended purpose, their fulfilment of the essential requirements and their effectiveness and performance are adequately proven.</p>
<p><sup>2</sup> When assessing the risks under paragraph 1, Swissmedic shall in particular take account of the procurement needs identified by the FOPH for preventing and combating the coronavirus in Switzerland.</p>
<p><sup>3</sup> Authorisation shall be granted to the Swiss distributor or the applicant institution or healthcare facility. It may be made subject to a time limit and other conditions and requirements.</p>
<p><sup>4</sup> Facemasks which have not undergone a conformity assessment procedure under Article 23 MedDO may be placed on the market without authorisation under paragraph 1 provided they:</p>
<dl>
<dt>a. </dt>
<dd>are placed on the market exclusively for non-medical use; and</dd>
<dt>b. </dt>
<dd>are expressly labelled as being for non-medical use.</dd>
</dl>
<p><sup>5</sup> Facemasks placed on the market in accordance with paragraph 3<sup>bis</sup> may not be used in hospitals or medical practices by persons in direct contact with patients.</p>
<p><sup>5bis</sup> The SwissCovid app as specified in the Ordinance of 24 June 2020<sup><a href="#fn-d6e968" id="fnbck-d6e968">50</a></sup> on the Proximity Tracing System for the Coronavirus Sars-CoV-2 and as specified in the Ordinance of 30 June 2021<sup><a href="#fn-d6e976" id="fnbck-d6e976">51</a></sup> on a Notification System for possible Infection with the Coronavirus Sars-CoV-2 at Events is not subject to the provisions on the conformity assessment of medical devices.<sup><a href="#fn-d6e984" id="fnbck-d6e984">52</a></sup></p>
<p><sup>6</sup> The obligations in relation to product surveillance under the MedDO, in particular to collecting reports of incidents, continue to apply.</p>
<div class="footnotes">
<p id="fn-d6e912"><sup><a href="#fnbck-d6e912">47</a></sup> Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/507" target="_blank">AS <b>2021</b> 507</a>).</p>
<p id="fn-d6e927"><sup><a href="#fnbck-d6e927">48</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2020/552" target="_blank">SR <b>812.213</b></a></p>
<p id="fn-d6e935"><sup><a href="#fnbck-d6e935">49</a></sup> The reference was amended on 26 May 2021 pursuant to Art. 12 para. 2 of the Publications Act of 18 June 2004 (<a href="https://fedlex.data.admin.ch/eli/cc/2004/745" target="_blank">SR <b>170.512</b></a>). The amendment has been made throughout the text.</p>
<p id="fn-d6e968"><sup><a href="#fnbck-d6e968">50</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2022/207" target="_blank">SR <b>818.101.25</b></a></p>
<p id="fn-d6e976"><sup><a href="#fnbck-d6e976">51</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2021/411" target="_blank">SR <b>818.102.4</b></a></p>
<p id="fn-d6e984"><sup><a href="#fnbck-d6e984">52</a></sup> Inserted by Art. 18 of the O of 30 June 2021 on a Notification System for possible Infection with the Coronavirus Sars-CoV-2 at Events, in force from 1 July 2021 until 30 June 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/411" target="_blank">AS <b>2021</b> 411</a>).</p>
</div>
</div></article><article id="art_23_a"><a name="a23a"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_23_a"><b>Art. 23</b><i>a</i></a><sup><a href="#fn-d6e1000" id="fnbck-d6e1000">53</a></sup>
</h6>
<div class="collapseable"><div class="footnotes"><p id="fn-d6e1000"><sup><a href="#fnbck-d6e1000">53</a></sup> Inserted by No I of the O of 12 March 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/145" target="_blank">AS <b>2021</b> 145</a>). Repealed by  No I of the O of 23 June 2021, with effect from 26 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/378" target="_blank">AS <b>2021</b> 378</a>).</p></div></div></article><article id="art_23_b"><a name="a23b"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_23_b"><b>Art. 23</b><i>b</i></a><sup><a href="#fn-d6e1020" id="fnbck-d6e1020">54</a></sup><a href="#art_23_b"><b></b> <b></b>Exception for FFP masks</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> FFP masks that do not comply with the principles and procedures for conformity assessment under Article 3 paragraph 2 of the PPE Ordinance of 25 October 2017<sup><a href="#fn-d6e1041" id="fnbck-d6e1041">55</a></sup> (PPEO) and whose non-compliance with these principles and procedure has not been approved based on Article 24 paragraph 3 in its version of 22 June 2020<sup><sup><a href="#fn-d6e1050" id="fnbck-d6e1050">56</a></sup></sup> may not be placed on the market.</p>
<p><sup>2</sup> FFP masks under paragraph 1 held in federal and cantonal stocks may be supplied to private hospitals, homes for the elderly and care homes and organisations that provide nursing services and other assistance at home as well as to federal and cantonal facilities such as the armed forces, civil defence units, hospitals and prisons provided the federal or cantonal authority responsible for the supply:</p>
<dl>
<dt>a. </dt>
<dd>guarantees by means of testing by a recognised European conformity assessment body for FFP masks that the masks provide a level of safety equivalent to that legally required under the PPEO; and</dd>
<dt>b. </dt>
<dd>guarantees their traceability.</dd>
</dl>
<p><sup>3</sup> Product information in at least one official language or in English must be available when the masks are supplied. It must be ensured that the user is able to use the product in accordance with the relevant provisions.</p>
<div class="footnotes">
<p id="fn-d6e1020"><sup><a href="#fnbck-d6e1020">54</a></sup> Originally Art. 23<i>a</i>. Inserted by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks), in force since 28 Jan. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/54" target="_blank">AS <b>2021</b> 54</a>).</p>
<p id="fn-d6e1041"><sup><a href="#fnbck-d6e1041">55</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2017/635" target="_blank">SR <b>930.115</b></a></p>
<p id="fn-d6e1050"><sup><a href="#fnbck-d6e1050">56</a></sup>  <a href="https://fedlex.data.admin.ch/eli/oc/2020/438" target="_blank">AS <b>2020</b> 2195</a></p>
</div>
</div></article><article id="art_24"><a name="a24"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_24"><b>Art. 24</b></a><sup><a href="#fn-d6e1075" id="fnbck-d6e1075">57</a></sup><a href="#art_24"><b></b> <b></b>Sars-CoV-2 rapid tests for specialist use and the supply and use of Sars-CoV-2 self-tests</a><sup><a href="#fn-d6e1088" id="fnbck-d6e1088">58</a></sup>
</h6>
<div class="collapseable"> <p><sup>1</sup> Non-automated single-patient rapid tests for direct detection of Sars-CoV-2 (Sars-CoV-2 rapid tests) for specialist use may only be carried out in the following facilities:<sup><a href="#fn-d6e1103" id="fnbck-d6e1103">59</a></sup></p>
<dl>
<dt>a.<sup><a href="#fn-d6e1116" id="fnbck-d6e1116">60</a></sup> </dt>
<dd>laboratories licensed under Article 16 EpidA;</dd>
<dt>b.<sup><a href="#fn-d6e1130" id="fnbck-d6e1130">61</a></sup> </dt>
<dd>medical practices, pharmacies and hospitals, homes for the elderly and care homes and socio-medical institutions, and test centres operated by or on behalf of the canton.</dd>
</dl>
<p><sup>1bis</sup> They may also be carried out in and by organisations that provide nursing services and other assistance at home as well as by assistants as defined in the Federal Act of 19 June 1959<sup><a href="#fn-d6e1144" id="fnbck-d6e1144">62</a></sup> on Invalidity Insurance (InvIA).<sup><a href="#fn-d6e1152" id="fnbck-d6e1152">63</a></sup></p>
<p><sup>2</sup> Sars-CoV-2 rapid tests may also be carried out at a location outside the facilities mentioned in paragraph 1 letter b provided a specialist with a CET qualification awarded by the Swiss «The Medical Laboratories of Switzerland» Federation (FAMH), a doctor or a pharmacist accepts responsibility for complying with the requirements of this article and Articles 24<i>a</i> and 24<i>b</i>.<sup><a href="#fn-d6e1173" id="fnbck-d6e1173">64</a></sup> </p>
<p><sup>3</sup> If facilities under paragraph 1 letter a offer Sars-CoV-2 rapid tests at a location outside the facilities, they must notify the canton of their offer.<sup><a href="#fn-d6e1186" id="fnbck-d6e1186">65</a></sup> </p>
<p><sup>4</sup> Facilities under paragraphs 1 letter b and 1<sup>bis</sup> may carry out Sars-CoV-2 rapid tests for specialist use without a licence under Article 16 EpidA and outside closed systems provided they comply with the following conditions:<sup><a href="#fn-d6e1201" id="fnbck-d6e1201">66</a></sup></p>
<dl>
<dt>a. </dt>
<dd>Suitable safety measures and precautionary measures plans to protect persons, animals, the environment and biological diversity have been prepared and implemented.</dd>
<dt>b.<sup><a href="#fn-d6e1217" id="fnbck-d6e1217">67</a></sup> </dt>
<dd>The tests are only carried out by persons specifically trained for this purpose according to the instructions provided by the test manufacturer. </dd>
<dt>c. </dt>
<dd>The test results are interpreted under the supervision of persons with the required expertise; external experts may also be consulted.</dd>
<dt>d. </dt>
<dd>The facilities keep records that permit the traceability and prove the quality of the test systems used. The records must be preserved.</dd>
<dt>e.  </dt>
<dd>The facilities are authorised by the canton to carry out such tests.</dd>
</dl>
<p><sup>4bis</sup> Sars-CoV-2 rapid tests for self-testing by the public (Sars-CoV-2 self-tests) may be supplied and used if they are intended for self-testing by the manufacturer and certified accordingly.<sup><a href="#fn-d6e1240" id="fnbck-d6e1240">68</a></sup> </p>
<p><sup>5</sup> Sars-CoV-2 rapid tests are direct detection methods that detect the antigens to Sars-CoV-2. The tests are not automated and are carried out with the minimum of instruments; only the reading of the test result may be automated.<sup><a href="#fn-d6e1258" id="fnbck-d6e1258">69</a></sup> </p>
<div class="footnotes">
<p id="fn-d6e1075"><sup><a href="#fnbck-d6e1075">57</a></sup> Amended by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests), in force since  21 Dec. 2020 (<a href="https://fedlex.data.admin.ch/eli/oc/2020/977" target="_blank">AS <b>2020</b> 5801</a>).</p>
<p id="fn-d6e1088"><sup><a href="#fnbck-d6e1088">58</a></sup> Amended by No I of the O of 12 March 2021, in force since 15 March 2021  (<a href="https://fedlex.data.admin.ch/eli/oc/2021/145" target="_blank">AS <b>2021</b> 145</a>).</p>
<p id="fn-d6e1103"><sup><a href="#fnbck-d6e1103">59</a></sup> Amended by No I of the O of 23 June 2021, in force since 26 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/378" target="_blank">AS <b>2021</b> 378</a>).</p>
<p id="fn-d6e1116"><sup><a href="#fnbck-d6e1116">60</a></sup> Amended by No I of the O of 21 Dec. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p>
<p id="fn-d6e1130"><sup><a href="#fnbck-d6e1130">61</a></sup> Amended by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks), in force since 28 Jan. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/54" target="_blank">AS <b>2021</b> 54</a>).</p>
<p id="fn-d6e1144"><sup><a href="#fnbck-d6e1144">62</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/1959/827_857_845" target="_blank">SR <b>831.20</b></a></p>
<p id="fn-d6e1152"><sup><a href="#fnbck-d6e1152">63</a></sup> Inserted by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks)  (<a href="https://fedlex.data.admin.ch/eli/oc/2021/54" target="_blank">AS <b>2021</b> 54</a>). Amended by No I of the O of 12 March 2021, in force since 15 March 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/145" target="_blank">AS <b>2021</b> 145</a>).</p>
<p id="fn-d6e1173"><sup><a href="#fnbck-d6e1173">64</a></sup> Amended by No I of the O of 21 Dec. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p>
<p id="fn-d6e1186"><sup><a href="#fnbck-d6e1186">65</a></sup> Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/507" target="_blank">AS <b>2021</b> 507</a>).</p>
<p id="fn-d6e1201"><sup><a href="#fnbck-d6e1201">66</a></sup> Amended by No I of the O of 12 March 2021, in force since 15 March 2021  (<a href="https://fedlex.data.admin.ch/eli/oc/2021/145" target="_blank">AS <b>2021</b> 145</a>).</p>
<p id="fn-d6e1217"><sup><a href="#fnbck-d6e1217">67</a></sup> Amended by No I of the O of 12 March 2021, in force since 15 March 2021  (<a href="https://fedlex.data.admin.ch/eli/oc/2021/145" target="_blank">AS <b>2021</b> 145</a>).</p>
<p id="fn-d6e1240"><sup><a href="#fnbck-d6e1240">68</a></sup> Inserted by No I of the O of 12 March 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/145" target="_blank">AS <b>2021</b> 145</a>). Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/507" target="_blank">AS <b>2021</b> 507</a>).</p>
<p id="fn-d6e1258"><sup><a href="#fnbck-d6e1258">69</a></sup> Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/507" target="_blank">AS <b>2021</b> 507</a>).</p>
</div>
</div></article><article id="art_24_a"><a name="a24a"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_24_a"><b>Art. 24</b><i>a</i></a><sup><a href="#fn-d6e1272" id="fnbck-d6e1272">70</a></sup><a href="#art_24_a"> Permitted Sars-CoV-2 rapid tests for specialist use</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> The only test systems that may be used for Sars-CoV-2 rapid tests for specialist use are those authorised in the EU for issuing the EU’s digital COVID certificate.</p>
<p><sup>2</sup> In derogation from paragraph 1, other test systems may also be used provided the Sars-CoV-2 rapid tests are carried out by laboratories licensed under Article 16 EpidA.<sup><a href="#fn-d6e1296" id="fnbck-d6e1296">71</a></sup></p>
<div class="footnotes">
<p id="fn-d6e1272"><sup><a href="#fnbck-d6e1272">70</a></sup> Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests) (<a href="https://fedlex.data.admin.ch/eli/oc/2020/977" target="_blank">AS <b>2020</b> 5801</a>). Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/507" target="_blank">AS <b>2021</b> 507</a>).</p>
<p id="fn-d6e1296"><sup><a href="#fnbck-d6e1296">71</a></sup> Amended by No I of the O of 21 Dec. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p>
</div>
</div></article><article id="art_24_b"><a name="a24b"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_24_b"><b>Art. 24</b><i>b</i></a><sup><a href="#fn-d6e1309" id="fnbck-d6e1309">72</a></sup><a href="#art_24_b"> Notifying the canton of a positives test result in the absence of a confirmatory diagnosis</a>
</h6>
<div class="collapseable"> <p>If no confirmatory diagnosis is made following a positive result for a Sars-CoV-2 rapid test and if the FDHA has not required a report on the result of Sars-CoV-2 rapid tests on the basis of Article 19 of the Epidemics Ordinance of 29 April 2015<sup><a href="#fn-d6e1329" id="fnbck-d6e1329">73</a></sup>, the facility or person responsible for conducting the tests must notify the cantonal authority or organisation responsible for contact tracing of the positive test result.</p>
<div class="footnotes">
<p id="fn-d6e1309"><sup><a href="#fnbck-d6e1309">72</a></sup> Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests) (<a href="https://fedlex.data.admin.ch/eli/oc/2020/977" target="_blank">AS <b>2020</b> 5801</a>). Amended by No I of the O of 12 March 2021, in force since 15 March 2021  (<a href="https://fedlex.data.admin.ch/eli/oc/2021/145" target="_blank">AS <b>2021</b> 145</a>).</p>
<p id="fn-d6e1329"><sup><a href="#fnbck-d6e1329">73</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2015/298" target="_blank">SR <b>818.101.1</b></a></p>
</div>
</div></article><article id="art_24_c"><a name="a24c"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_24_c"><b>Art. 24</b><i>c</i></a><sup><a href="#fn-d6e1341" id="fnbck-d6e1341">74</a></sup><a href="#art_24_c"> Lists of Sars-CoV-2 rapid tests</a>
</h6>
<div class="collapseable"> <p>The FOPH shall maintain continuously updated lists of Sars-CoV-2 rapid tests for specialist use in accordance with Article 24<i>a </i>and the<i> </i>Sars-CoV-2 self-tests in accordance with Article 24 paragraph 4<sup>bis</sup> and shall publish the lists on its website.</p>
<div class="footnotes"><p id="fn-d6e1341"><sup><a href="#fnbck-d6e1341">74</a></sup> Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests) (<a href="https://fedlex.data.admin.ch/eli/oc/2020/977" target="_blank">AS <b>2020</b> 5801</a>). Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/507" target="_blank">AS <b>2021</b> 507</a>).</p></div>
</div></article><article id="art_24_d"><a name="a24d"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_24_d"><b>Art. 24</b><i>d</i></a><sup><a href="#fn-d6e1371" id="fnbck-d6e1371">75</a></sup><a href="#art_24_d"> Responsibility of the cantons for carrying out Sars-CoV-2 rapid tests</a>
</h6>
<div class="collapseable"> <p>The cantons are responsible for monitoring and enforcing compliance with the conditions in Articles 24–24<i>b</i> for Sars-CoV-2 rapid tests that are not carried out at the facilities referred to in Article 24 paragraph 1 letter a.</p>
<div class="footnotes"><p id="fn-d6e1371"><sup><a href="#fnbck-d6e1371">75</a></sup> Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests) (<a href="https://fedlex.data.admin.ch/eli/oc/2020/977" target="_blank">AS <b>2020</b> 5801</a>). Amended by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks), in force since 28 Jan. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/54" target="_blank">AS <b>2021</b> 54</a>).</p></div>
</div></article><article id="art_24_e"><a name="a24e"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_24_e"><b>Art. 24</b><i>e</i></a><sup><a href="#fn-d6e1397" id="fnbck-d6e1397">76</a></sup><a href="#art_24_e"> Collecting samples for molecular-biological analyses for Sars-CoV-2</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> Samples for molecular-biological analyses for Sars-CoV-2 may be collected:</p>
<dl>
<dt>a. </dt>
<dd>in laboratories licensed under Article 16 EpidA and in sample collection stations that they operate; </dd>
<dt>b. </dt>
<dd>in facilities or by persons in accordance with Article 24 paragraphs 1 letter b, 1<sup>bis</sup> and 2;</dd>
<dt>c.<sup><a href="#fn-d6e1426" id="fnbck-d6e1426">77</a></sup> </dt>
<dd>…</dd>
</dl>
<p><sup>2</sup> The sample collection station must verify the identity of the person being tested. The sample must be collected by a person trained for this purpose.</p>
<p><sup>3</sup> The sample may also be collected by the person being tested themselves:</p>
<dl>
<dt>a. </dt>
<dd>in the facility, provided the facility verifies the identity of the person being tested and supervises the collection of the sample as it is being done; or</dd>
<dt>b. </dt>
<dd>outside the facility, provided the facility verifies the identity of the person being tested and guarantees that the sample is correctly assigned to the person being tested by taking suitable precautions, in particular by the video monitoring of the process.</dd>
</dl>
<div class="footnotes">
<p id="fn-d6e1397"><sup><a href="#fnbck-d6e1397">76</a></sup> Inserted by No I of the O of 25 Aug. 2021, in force since 1 Oct. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/507" target="_blank">AS <b>2021</b> 507</a>).</p>
<p id="fn-d6e1426"><sup><a href="#fnbck-d6e1426">77</a></sup> Repealed by No I of the O of 21 Dec. 2022, with effect from 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p>
</div>
</div></article><article id="art_24_f"><a name="a24f"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_24_f"><b>Art. 24</b><i>f</i></a><sup><a href="#fn-d6e1455" id="fnbck-d6e1455">78</a></sup><a href="#art_24_f"> Responsibility for monitoring the collection of samples for molecular-biological analyses for Sars-CoV-2</a>
</h6>
<div class="collapseable"> <p>Swissmedic is responsible for monitoring compliance with the requirements set out in Article 24<i>e</i> by laboratories licensed under Article 16 EpidA and the cantons are responsible for monitoring in the facilities in accordance with Article 24<i>e</i> paragraph 1 letter b.</p>
<div class="footnotes"><p id="fn-d6e1455"><sup><a href="#fnbck-d6e1455">78</a></sup> Inserted by No I of the O of 25 Aug. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/507" target="_blank">AS <b>2021</b> 507</a>). Amended by No I of the O of 21 Dec. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div>
</div></article><article id="art_24_f_bis"><a name="a24fbis"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_24_f_bis"><b>Art. 24</b><i>f</i><sup>bis </sup></a><sup><a href="#fn-d6e1484" id="fnbck-d6e1484">79</a></sup><a href="#art_24_f_bis"><i></i> <i></i>Conducting molecular-biological analyses for  Sars-CoV-2 abroad</a>
</h6>
<div class="collapseable"> <br><p>Only laboratories with a licence under Article 16 EpidA may commission a foreign laboratory to conduct molecular-biological analyses for Sars-CoV-2. They remain subject to the requirement to report under Article 12 EpidA.</p>
<div class="footnotes"><p id="fn-d6e1484"><sup><a href="#fnbck-d6e1484">79</a></sup> Inserted by No I of the O of 16 Feb. 2022, in force since 15 March 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/96" target="_blank">AS <b>2022</b> 96</a>).</p></div>
</div></article><article id="art_24_g"><a name="a24g"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_24_g"><b>Art. 24</b><i>g</i></a><sup><a href="#fn-d6e1507" id="fnbck-d6e1507">80</a></sup><a href="#art_24_g"> Disclosure of data</a>
</h6>
<div class="collapseable"> <p>Swissmedic may disclose data on essential medical goods to the federal offices and organisations mentioned in Article 12 paragraph 1, provided this is required in order to implement this Ordinance. The data must not include sensitive personal data.</p>
<div class="footnotes"><p id="fn-d6e1507"><sup><a href="#fnbck-d6e1507">80</a></sup> Originally Art. 24<i>e</i>. Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests), in force since 21 Dec. 2020 (<a href="https://fedlex.data.admin.ch/eli/oc/2020/977" target="_blank">AS <b>2020</b> 5801</a>).</p></div>
</div></article>
</div></section>
</div></section><section id="chap_3"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#chap_3">Chapter 3 Healthcare Provision</a>
</h1>
<div class="collapseable"> <article id="art_25"><a name="a25"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_25"><b>Art. 25</b><b></b> <b></b>Hospitals and clinics</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> The cantons shall ensure that sufficient capacities (in particular beds and specialist staff) are available in the inpatient departments of hospitals and clinics for COVID-19 patients and for other urgently required medical examinations and treatments, in particular in the intensive care units and the general internal medicine departments.</p>
<p><sup>2</sup> For this purpose, they may require hospitals and clinics:</p>
<dl>
<dt>a. </dt>
<dd>to make their inpatient capacities available immediately or on demand; and</dd>
<dt>b. </dt>
<dd>to restrict or suspend non-urgent medical procedures and treatments.</dd>
</dl>
<p><sup>3</sup> The hospitals and clinics must ensure that supplies of medicinal products for COVID-19 patients and for other urgently required medical examinations and treatments is guaranteed in their outpatient and inpatient departments.</p>
</div></article><article id="art_25_a"><a name="a25a"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_25_a"><b>Art. 25</b><i>a</i></a><sup><a href="#fn-d6e1557" id="fnbck-d6e1557">81</a></sup><a href="#art_25_a"> Duty of the cantons to report healthcare capacities</a>
</h6>
<div class="collapseable"> <p>The cantons shall be required to report the following regularly to the Coordinated Medical Services:</p>
<dl>
<dt>a. </dt>
<dd>the total number and occupancy of hospital beds;</dd>
<dt>b. </dt>
<dd>the total number and occupancy of hospital beds intended for treating COVID-19 patients, as well as the number of COVID-19 patients currently being treated;</dd>
<dt>c. </dt>
<dd>the total number and occupancy of intensive care beds and the number of COVID-19 patients currently being treated and being ventilated in intensive care;</dd>
<dt>d. </dt>
<dd>the total number and usage of extracorporeal membrane oxygenation devices (ECMO);</dd>
<dt>e. </dt>
<dd>the availability of medical and nursing staff in hospitals;</dd>
<dt>f. </dt>
<dd>the maximum capacities, i.e. the total number of patients and of COVID-19 patients that can be treated in their hospitals taking into consideration the numbers of available beds and of available staff.</dd>
</dl>
<div class="footnotes"><p id="fn-d6e1557"><sup><a href="#fnbck-d6e1557">81</a></sup> Inserted by Annex No 2 of the COVID-19 Special Situation Ordinance of 16 Feb. 2022, in force since 17 Feb. 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/97" target="_blank">AS <b>2022</b> 97</a>).</p></div>
</div></article><article id="art_26"><a name="a26"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_26"><b>Art. 26</b></a><sup><a href="#fn-d6e1594" id="fnbck-d6e1594">82</a></sup>
</h6>
<div class="collapseable"><div class="footnotes"><p id="fn-d6e1594"><sup><a href="#fnbck-d6e1594">82</a></sup> Repealed by No I of the O of 21 Dec. 2022, with effect from 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div></div></article><article id="art_26_a"><a name="a26a"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_26_a"><b>Art. 26</b><i>a</i></a><sup><a href="#fn-d6e1609" id="fnbck-d6e1609">83</a></sup>
</h6>
<div class="collapseable"><div class="footnotes"><p id="fn-d6e1609"><sup><a href="#fnbck-d6e1609">83</a></sup> Inserted by No I of the O of 24 June 2020 (<a href="https://fedlex.data.admin.ch/eli/oc/2020/467" target="_blank">AS <b>2020</b> 2549</a>). Repealed by No I of the O of 21 Dec. 2022, with effect from 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div></div></article><article id="art_26_b"><a name="a26b"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_26_b"><b>Art. 26</b><i>b</i> and <b>26</b><i>c</i></a><sup><a href="#fn-d6e1632" id="fnbck-d6e1632">84</a></sup>
</h6>
<div class="collapseable"><div class="footnotes"><p id="fn-d6e1632"><sup><a href="#fnbck-d6e1632">84</a></sup> Inserted by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP masks) (<a href="https://fedlex.data.admin.ch/eli/oc/2021/54" target="_blank">AS <b>2021</b> 54</a>). Repealed by No I of the O of 21 Dec. 2022, with effect from 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div></div></article>
</div></section><section id="chap_4"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#chap_4">Chapter 4 …</a>
</h1>
<div class="collapseable"><article id="art_27"><a name="a27"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_27"><b>Art. 27</b></a><sup><a href="#fn-d6e1653" id="fnbck-d6e1653">85</a></sup>
</h6>
<div class="collapseable"><div class="footnotes"><p id="fn-d6e1653"><sup><a href="#fnbck-d6e1653">85</a></sup> Repealed by No I of the O of 21 Dec. 2022, with effect from 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div></div></article></div></section><section id="chap_4_a"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#chap_4_a">Chapter 4<i>a</i> …</a>
</h1>
<div class="collapseable"><article id="art_27_a"><a name="a27a"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_27_a"><b>Art. 27</b><i>a</i></a><sup><a href="#fn-d6e1673" id="fnbck-d6e1673">86</a></sup>
</h6>
<div class="collapseable"><div class="footnotes"><p id="fn-d6e1673"><sup><a href="#fnbck-d6e1673">86</a></sup> Inserted by No I of the O of 13 Jan. 2021 (Employees at High Risk) (<a href="https://fedlex.data.admin.ch/eli/oc/2021/5" target="_blank">AS <b>2021</b> 5</a>). Amended by No I of the O of 17. Dez. 2021, in force from 1 Jan. 2022 to 31 March 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/881" target="_blank">AS <b>2021</b> 881</a>; Art. 29 para. 7).</p></div></div></article></div></section><section id="chap_5"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#chap_5">Chapter 5 Final Provisions</a>
</h1>
<div class="collapseable"> <article id="art_28"><a name="a28"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_28"><b>Art. 28</b> <inl name="w:shd" md="S" id="d7e7104" xmlns:tmp="urn:com:c-moria:legi4ch:xslt:temp"></inl>Repeal <inl md="E" id="d7e7104" xmlns:tmp="urn:com:c-moria:legi4ch:xslt:temp"></inl>of another<inl name="w:shd" md="S" id="d7e7114" xmlns:tmp="urn:com:c-moria:legi4ch:xslt:temp"></inl> enactment<inl md="E" id="d7e7114" xmlns:tmp="urn:com:c-moria:legi4ch:xslt:temp"></inl></a>
</h6>
<div class="collapseable"> <p>The COVID-19 Ordinance 2 of 13 March 2020<sup><a href="#fn-d6e1708" id="fnbck-d6e1708">87</a></sup> is repealed.</p>
<div class="footnotes"><p id="fn-d6e1708"><sup><a href="#fnbck-d6e1708">87</a></sup>  [<a href="https://fedlex.data.admin.ch/eli/oc/2020/141" target="_blank">AS <b>2020 </b>773</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/144" target="_blank">783</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/158" target="_blank">841</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/164" target="_blank">863</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/165" target="_blank">867</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/188" target="_blank">1059</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/190" target="_blank">1065</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/196" target="_blank">1101</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/206" target="_blank">1131</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/207" target="_blank">1137</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/213" target="_blank">1155</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/225" target="_blank">1199</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/238" target="_blank">1245</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/239" target="_blank">1249</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/252" target="_blank">1333</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/275" target="_blank">1401</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/299" target="_blank">1501</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/300" target="_blank">1505</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/323" target="_blank">1585</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/343" target="_blank">1751</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/366" target="_blank">1815</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/367" target="_blank">1823</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/371" target="_blank">1835</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/413" target="_blank">2097</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/414" target="_blank">2099</a>, <a href="https://fedlex.data.admin.ch/eli/oc/2020/439" target="_blank">2213 </a>art. 14 n. II]</p></div>
</div></article><article id="art_28_a"><a name="a28a"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_28_a"><b>Art. 28</b><i>a</i></a><sup><a href="#fn-d6e1801" id="fnbck-d6e1801">88</a></sup><a href="#art_28_a"><i></i> <i></i>Transitional provision to the Amendment of 11 September 2020</a>
</h6>
<div class="collapseable"> <p>Personal protective equipment that was permitted under Article 24 of the previous law may continue to be placed on the market until 30 June 2021.</p>
<div class="footnotes"><p id="fn-d6e1801"><sup><a href="#fnbck-d6e1801">88</a></sup> Inserted by No I of the O of 11 Sept. 2020 (Extension; Test Costs), in force since 18 Sept. 2020 (<a href="https://fedlex.data.admin.ch/eli/oc/2020/671" target="_blank">AS <b>2020</b> 3695</a>).</p></div>
</div></article><article id="art_28_b"><a name="a28b"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_28_b"><b>Art. 28</b><i>b</i></a><sup><a href="#fn-d6e1823" id="fnbck-d6e1823">89</a></sup><a href="#art_28_b"> Transitional provisions to the Amendment of 23 June 2021</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> …<sup><a href="#fn-d6e1839" id="fnbck-d6e1839">90</a></sup></p>
<p><sup>2</sup> Pharmacies may continue to supply Sars-CoV-2 self-tests licensed under Article 23<i>a </i>of the previous law provided the requirements of Article 24 paragraph 4<sup>bis</sup> letter b are met.</p>
<p><sup>3</sup> …<sup><a href="#fn-d6e1858" id="fnbck-d6e1858">91</a></sup></p>
<div class="footnotes">
<p id="fn-d6e1823"><sup><a href="#fnbck-d6e1823">89</a></sup> Inserted by No I of the O of 23 June 2021, in force since 26 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/378" target="_blank">AS <b>2021</b> 378</a>).</p>
<p id="fn-d6e1839"><sup><a href="#fnbck-d6e1839">90</a></sup> Repealed by No I of the O of 16 Feb. 2022, with effect from 17 Feb. 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/96" target="_blank">AS <b>2022</b> 96</a>).</p>
<p id="fn-d6e1858"><sup><a href="#fnbck-d6e1858">91</a></sup> Repealed by No I of the O of 16 Feb. 2022, with effect from 17 Feb. 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/96" target="_blank">AS <b>2022</b> 96</a>).</p>
</div>
</div></article><article id="art_28_c"><a name="a28c"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_28_c"><b>Art. 28</b><i>c</i></a><sup><a href="#fn-d6e1871" id="fnbck-d6e1871">92</a></sup>
</h6>
<div class="collapseable"><div class="footnotes"><p id="fn-d6e1871"><sup><a href="#fnbck-d6e1871">92</a></sup> Inserted by No I of the O of 25. Aug. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/507" target="_blank">AS <b>2021</b> 507</a>). Repealed by No I of the O of 16 Feb. 2022, with effect from 17 Feb. 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/96" target="_blank">AS <b>2022</b> 96</a>).</p></div></div></article><article id="art_28_d"><a name="a28d"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_28_d"><b>Art. 28</b><i>d</i></a><sup><a href="#fn-d6e1891" id="fnbck-d6e1891">93</a></sup><a href="#art_28_d"><i></i> <i></i>Transitional provision to the Amendment of 21 December 2022</a>
</h6>
<div class="collapseable"> <p>The costs of analyses for Sars-CoV-2 for which a sample is taken before the Amendment of 21 December 2022 comes into force shall be covered in accordance with Articles 26–26<i>c </i>of the previous law.</p>
<div class="footnotes"><p id="fn-d6e1891"><sup><a href="#fnbck-d6e1891">93</a></sup> Inserted by No I of the O of 21 Dec. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div>
</div></article><article id="art_29"><a name="a29"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_29"><b>Art. 29</b> Commencement and term</a>
</h6>
<div class="collapseable"> <p><sup>1</sup> This Ordinance comes into force on 22 June 2020 at 00.00.</p>
<p><sup>2</sup> It applies until 13 September 2020.<sup><a href="#fn-d6e1924" id="fnbck-d6e1924">94</a></sup></p>
<p><sup>3</sup> ...<sup><a href="#fn-d6e1936" id="fnbck-d6e1936">95</a></sup></p>
<p><sup>4</sup> The term of application of this Ordinance shall be extended to 31 December 2021, subject to paragraph 5.<sup><a href="#fn-d6e1948" id="fnbck-d6e1948">96</a></sup></p>
<p><sup>5</sup> …<sup><a href="#fn-d6e1965" id="fnbck-d6e1965">97</a></sup></p>
<p><sup>6</sup> The term of application of this Ordinance shall be extended to 31 December 2022, subject to paragraphs 5 and 7.<sup><a href="#fn-d6e1982" id="fnbck-d6e1982">98</a></sup></p>
<p><sup>7</sup> Article 27<i>a</i> and Annex 7 apply until 31 March 2022.<sup><a href="#fn-d6e1996" id="fnbck-d6e1996">99</a></sup></p>
<p><sup>8</sup> The period of validity of this Ordinance shall be extended to 30 June 2024.<sup><a href="#fn-d6e2008" id="fnbck-d6e2008">100</a></sup></p>
<div class="footnotes">
<p id="fn-d6e1924"><sup><a href="#fnbck-d6e1924">94</a></sup> Amended by No II of the O of 12 Aug. 2020 (Requirement to wear Masks in Aircraft; Large-scale Events), in force since 15 Aug. 2020 (<a href="https://fedlex.data.admin.ch/eli/oc/2020/625" target="_blank">AS <b>2020</b> 3547</a>).</p>
<p id="fn-d6e1936"><sup><a href="#fnbck-d6e1936">95</a></sup> Repealed by No II of the O of 12 Aug. 2020 (Requirement to wear Masks in Aircraft; Large-scale Events), with effect from 15 Aug. 2020 (<a href="https://fedlex.data.admin.ch/eli/oc/2020/625" target="_blank">AS <b>2020</b> 3547</a>).</p>
<p id="fn-d6e1948"><sup><a href="#fnbck-d6e1948">96</a></sup> Inserted by No I of the O of 11 Sept. 2020 (Extension; Test Costs) (<a href="https://fedlex.data.admin.ch/eli/oc/2020/671" target="_blank">AS <b>2020</b> 3695</a>). Amended by No I of the O of 27 Oct. 2021, in force since 28 Oct. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/634" target="_blank">AS <b>2021</b> 634</a>).</p>
<p id="fn-d6e1965"><sup><a href="#fnbck-d6e1965">97</a></sup> Inserted by No I of the O of 27. Okt. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/634" target="_blank">AS <b>2021</b> 634</a>). Repealed by No I of the O of 21 Dec. 2022, with effect from 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p>
<p id="fn-d6e1982"><sup><a href="#fnbck-d6e1982">98</a></sup> Inserted by No I of the O of 17 Dec. 2021, in force since 1 Jan. 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/881" target="_blank">AS <b>2021</b> 881</a>).</p>
<p id="fn-d6e1996"><sup><a href="#fnbck-d6e1996">99</a></sup> Inserted by No I of the O of 17 Dec. 2021, in force since 1 Jan. 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/881" target="_blank">AS <b>2021</b> 881</a>).</p>
<p id="fn-d6e2008"><sup><a href="#fnbck-d6e2008">100</a></sup> Inserted by No I of the O of 21 Dec. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p>
</div>
</div></article>
</div></section></main><div id="annex">
<section id="annex_1"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1">Annex 1</a><sup><a href="#fn-d6e2021" id="fnbck-d6e2021">101</a></sup>
</h1>
<div class="footnotes"><p id="fn-d6e2021"><sup><a href="#fnbck-d6e2021">101</a></sup>  Amended by No I of the FDJP O of 21 April 2022, in force since 2 May 2022  (<a href="https://fedlex.data.admin.ch/eli/oc/2022/254" target="_blank">AS <b>2022</b> 254</a>).</p></div>
<div class="collapseable">
<p>(Art. 3 para. 3, 4 para. 2<sup>ter</sup> and Art. 5)</p>
<section id="annex_1/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1">List of high-risk countries and regions</a>
</h2>
<div class="collapseable">
<section id="annex_1/lvl_u1/lvl_1"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1/lvl_1">1. High-risk countries and regions (Art. 3 para. 2 let. a)</a>
</h3>
<div class="collapseable"><p><i>There are no entries currently on this list</i></p></div></section><section id="annex_1/lvl_u1/lvl_2"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1/lvl_u1/lvl_2">2. High-risk countries and regions with a variant of the Sars-CoV-2 virus that carries a higher risk of infection or causes a more severe form of the disease in comparison with the variant of the virus prevalent in the Schengen area (Art. 3 para. 2 let. b)</a>
</h3>
<div class="collapseable"><p><i>There are no entries currently on this list</i></p></div></section>
</div></section>
</div></section><section id="annex_1_a"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1_a">Annex 1a</a><sup><a href="#fn-d6e2047" id="fnbck-d6e2047">102</a></sup>
</h1>
<div class="footnotes"><p id="fn-d6e2047"><sup><a href="#fnbck-d6e2047">102</a></sup> Inserted by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/380" target="_blank">AS <b>2021</b> 380</a>). Amended by No II of the O of 18 March 2022, in force since 21 March 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/182" target="_blank">AS <b>2022</b> 182</a>).</p></div>
<div class="collapseable">
<p>(Art. 4 para. 2 let. a and a<sup>bis</sup> and Art. 5)</p>
<section id="annex_1_a/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1_a/lvl_u1">Persons who have been vaccinated and who have recovered</a>
</h2>
<div class="collapseable">
<section id="annex_1_a/lvl_u1/lvl_1"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1_a/lvl_u1/lvl_1">1 Persons who have been vaccinated</a>
</h3>
<div class="collapseable">
<dl>
<dt>1.1 </dt>
<dd>Persons who have been vaccinated are persons who have been vaccinated with a vaccine that:<dl>
<dt>a. </dt>
<dd>is authorised in Switzerland and which has been administered in full in accordance with the FOPH recommendations;</dd>
<dt>b. </dt>
<dd>has been authorised by the European Medicines Agency for the European Union and has been administered in full in accordance with the requirements or recommendations of the country in which the vaccination was administered; </dd>
<dt>c. </dt>
<dd>has been authorised under the WHO Emergency Use Listing and has been administered in full in accordance with the requirements or recommendations of the country in which the vaccination was administered; or</dd>
<dt>d. </dt>
<dd>has been shown to have the same composition as a vaccine licensed under letters a, b or c, but marketed by the licence holder under another name, and which has been administered in full in accordance with the requirements or recommendations of the country in which the vaccination was carried out.</dd>
</dl>
</dd>
<dt>1.2 </dt>
<dd>A vaccination is valid for 270 days from the date of vaccination in full or from the date of a booster vaccination following vaccination in full; the Janssen Ad26.COV2.S / COVID-19 vaccine is regarded as being effective for 270 days from the 22nd day after it was administered in full.</dd>
<dt>1.3 </dt>
<dd>Proof of vaccination may be provided in the form of a COVID-19 certificate in accordance with Article 1 letter a number 1 of the COVID-19 Ordinance on Certificates of 4 June 2021<sup><a href="#fn-d6e2093" id="fnbck-d6e2093">103</a></sup> or a recognised foreign certificate in accordance with Section 7 of the COVID-19 Ordinance on Certificates.</dd>
<dt>1.4 </dt>
<dd>Proof may also be provided in a different form from that in number 3. It must be a form of proof that is customary at the time. In addition to the surname, forename and date of birth of the person concerned, it must include the following information:<dl>
<dt>a. </dt>
<dd>the date of vaccination;</dd>
<dt>b. </dt>
<dd>the vaccine used.</dd>
</dl>
</dd>
</dl>
<div class="footnotes"><p id="fn-d6e2093"><sup><a href="#fnbck-d6e2093">103</a></sup>  <a href="https://fedlex.data.admin.ch/eli/cc/2021/325" target="_blank">SR <b>818.102.2</b></a></p></div>
</div></section><section id="annex_1_a/lvl_u1/lvl_2"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_1_a/lvl_u1/lvl_2">2 Persons who have recovered</a>
</h3>
<div class="collapseable"> <dl>
<dt>2.1 </dt>
<dd>Proof of recovery is valid for the following periods:<dl>
<dt>a. </dt>
<dd>in the case of a molecular-biological analysis for Sars-CoV-2: from the 11th to the 180th day following confirmation of the infection;</dd>
<dt>b. </dt>
<dd>in the case of a Sars-CoV-2 rapid test for specialist use or a laboratory-based immunological analysis for Sars-CoV-2, with the exception of tests and analyses based on a sample taken solely from the nasal cavity or on a saliva sample: from the 11th to the 180th day following confirmation of the infection;</dd>
<dt>c. </dt>
<dd>in the case of an analysis for Sars-CoV-2 antibodies: for the period of validity of the related certificate (Art. 34<i>a</i> para. 1 let. c of the COVID-19 Ordinance on Certificates  of 4 June 2021<sup><a href="#fn-d6e2131" id="fnbck-d6e2131">104</a></sup>);</dd>
</dl>
</dd>
<dt>2.2 </dt>
<dd>Proof of recovery may be provided in the form of a COVID-19 certificate under Article 1 letter a number 2 of the COVID-19 Ordinance on Certificates or a recognised foreign certificate under Section 7 of the COVID-19-Ordinance of Certificates.</dd>
<dt>2.3 </dt>
<dd>Proof may also be provided in forms other than in Number 2.2. It must be a form of proof that currently commonly accepted. It must, in addition to the surname, first name(s) and date of birth of the person concerned contain either of the following:<dl>
<dt>a. </dt>
<dd>confirmation of the infection, including the name and address of the confirming body (test centre, doctor, pharmacy, hospital);</dd>
<dt>b. </dt>
<dd>confirmation of the termination of isolation or a doctor’s confirmation of recovery.</dd>
</dl>
</dd>
</dl>
<div class="footnotes"><p id="fn-d6e2131"><sup><a href="#fnbck-d6e2131">104</a></sup> <a href="https://fedlex.data.admin.ch/eli/cc/2021/325" target="_blank">SR <b>818.102.2</b></a></p></div>
</div></section>
</div></section>
</div></section><section id="annex_2"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_2">Annex 2</a><sup><a href="#fn-d6e2155" id="fnbck-d6e2155">105</a></sup>
</h1>
<div class="footnotes"><p id="fn-d6e2155"><sup><a href="#fnbck-d6e2155">105</a></sup> Rendered obsolete by the repeal of Art. 8 (see Art. 6 No 1 of the COVID-19 Ordinance on International Travel Measures of 2 July 2020, <a href="https://fedlex.data.admin.ch/eli/oc/2020/496" target="_blank">AS <b>2020</b> 2737</a>).</p></div>
<div class="collapseable"></div></section><section id="annex_3"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_3">Annex 3</a><sup><a href="#fn-d6e2167" id="fnbck-d6e2167">106</a></sup>
</h1>
<div class="footnotes"><p id="fn-d6e2167"><sup><a href="#fnbck-d6e2167">106</a></sup> Amended by No I of the FDJP O of 27 Nov. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/780" target="_blank">AS <b>2021</b> 780</a>). Revised by No III of the O of 3 Dec. 2021, in force since 4 Dec. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/814" target="_blank">AS <b>2021</b> 814</a>).</p></div>
<div class="collapseable">
<p>(Art. 9 para. 3)</p>
<section id="annex_3/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_3/lvl_u1">Restrictions on cross-border movements of persons</a>
</h2>
<div class="collapseable"><p class=" man-font-style-italic ">There are no entries currently on this list.</p></div></section>
</div></section><section id="annex_4"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_4">Annex 4</a><sup><a href="#fn-d6e2190" id="fnbck-d6e2190">107</a></sup>
</h1>
<div class="footnotes"><p id="fn-d6e2190"><sup><a href="#fnbck-d6e2190">107</a></sup> Amended by No I of the FOPH O of 6 Oct. 2020 (List of important medical products and list of active substances for the treatment of COVID-19) (<a href="https://fedlex.data.admin.ch/eli/oc/2020/753" target="_blank">AS <b>2020</b> 4129</a>). Revised by No II para. 1 of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks) (<a href="https://fedlex.data.admin.ch/eli/oc/2021/54" target="_blank">AS <b>2021</b> 54</a>), No I para. 1 of the FDHA O of 14 April 2021 (Amendment of the lists of important medical products and of active substances for the treatment of COVID-19 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/212" target="_blank">AS <b>2021</b> 212</a>), No II of the O of 12 May 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/274" target="_blank">AS <b>2021</b> 274</a>), No I of the FDHA O of 17 Aug. 2021 (Amendment of the List of important medical products and list of active substances for the treatment of COVID-19) (<a href="https://fedlex.data.admin.ch/eli/oc/2021/493" target="_blank">AS <b>2021</b> 493</a>), No I para. 1 of the FDHA O of 23 March 2022 (Amendment of the List of important medical products and list of active substances for the treatment of COVID-19) (<a href="https://fedlex.data.admin.ch/eli/oc/2022/186" target="_blank">AS <b>2022</b> 186</a>) and No II para. 1 of the O of 21 Dec. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div>
<div class="collapseable">
<p>(Art. 11 para. 1, 19 para. 1 and 21 para. 2)</p>
<section id="annex_4/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_4/lvl_u1">List of important medicinal products, medical devices and protective equipment (Essential Medical Goods)</a>
</h2>
<div class="collapseable">
<section id="annex_4/lvl_u1/lvl_1"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_4/lvl_u1/lvl_1">1.  Active substances or medicinal products with the listed active substances</a>
</h3>
<div class="collapseable"> <p>  1. Tocilizumab</p>
<p>  2. Remdesivir</p>
<p>  3. Propofol</p>
<p>  4. Midazolam</p>
<p>  5. Ketamine</p>
<p>  6. Dexmedetomidine</p>
<p>  7. Dobutamine</p>
<p>  8. Sufentanil</p>
<p>  9. Remifentanyl</p>
<p>10. Rocuronium</p>
<p>11. Atracurium</p>
<p>12. Suxamethonium</p>
<p>13. Noradrenalin</p>
<p>14. Adrenalin</p>
<p>15. Insulin</p>
<p>16. Fentanyl</p>
<p>17. Heparin</p>
<p>18. Argatroban</p>
<p>19. Morphine</p>
<p>20. Paracetamol (parenteral)</p>
<p>21. Metamizol (parenteral)</p>
<p>22. Lorazepam</p>
<p>23. Dexamethasone</p>
<p>24. Co-Amoxicillin</p>
<p>25. Piperacillin/Tazobactam</p>
<p>26. Meropenem</p>
<p>27. Imipenem/Cilastatin</p>
<p>28. Cefuroxime</p>
<p>29. Ceftriaxone</p>
<p>30. Amikacin</p>
<p>31. Posaconazole</p>
<p>32. Fluconazole</p>
<p>33. Voriconazole</p>
<p>34. Caspofungin</p>
<p>35. Esmolol (parenteral)</p>
<p>36. Metoprolol (parenteral)</p>
<p>37. Labetalol (parenteral)</p>
<p>38. Clonidine</p>
<p>39. Amiodarone</p>
<p>40. Furosemide</p>
<p>41. Vaccines against COVID-19</p>
<p>42. Vaccines against influenza</p>
<p>43. Vaccines against bacterial pneumonia (Prevnar 13)</p>
<p>44. Medical gases</p>
<dl>
<dt>45. </dt>
<dd>Casirivimab/imdevimab</dd>
</dl>
<p>46. Nirmatrelvir (PF-07321332)/Ritonavir</p>
<p>47. Medical oxygen </p>
<p>48. Infusion solutions</p>
<p>49. Sotrovimab</p>
<p>50. Tixagevimab/Cilgavimab</p>
<p>51. Baricitinib</p>
</div></section><section id="annex_4/lvl_u1/lvl_2"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_4/lvl_u1/lvl_2">2.  Medical devices within the meaning of the Medical Devices Ordinance of 17 October 2001</a><sup><a href="#fn-d6e2348" id="fnbck-d6e2348">108</a></sup>
</h3>
<div class="footnotes"><p id="fn-d6e2348"><sup><a href="#fnbck-d6e2348">108</a></sup>  <a href="https://fedlex.data.admin.ch/eli/cc/2020/552" target="_blank">SR <b>812.213</b></a></p></div>
<div class="collapseable"> <p>1. Ventilators</p>
<p>2. Monitoring equipment for intensive care</p>
<p>3. In vitro diagnostics (COVID-19 tests), including pre-analytical components and instruments</p>
<p>4. Surgical masks / OP masks (hygiene masks)</p>
<p>5. Surgical gloves / examination gloves</p>
<p>6. Infusion sets</p>
<p>7. Pipette tips with filters</p>
<p>8. Test kits (tubes and swabs)</p>
<p>9. Single-use syringes and cannulae</p>
<p>10. Blood gas syringes</p>
</div></section><section id="annex_4/lvl_u1/lvl_3"><h3 class="heading" role="heading" aria-level="3">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_4/lvl_u1/lvl_3">3.  Personal protective equipment and other equipment</a>
</h3>
<div class="collapseable"> <section id="annex_4/lvl_u1/lvl_3/lvl_3_1"><h4 class="heading" role="heading" aria-level="4">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_4/lvl_u1/lvl_3/lvl_3_1">3.1 Personal protective equipment within the meaning of the PPE Ordinance of 25 October 2017</a><sup><a href="#fn-d6e2383" id="fnbck-d6e2383">109</a></sup>
</h4>
<div class="footnotes"><p id="fn-d6e2383"><sup><a href="#fnbck-d6e2383">109</a></sup>  <a href="https://fedlex.data.admin.ch/eli/cc/2017/635" target="_blank">SR <b>930.115</b></a></p></div>
<div class="collapseable"> <p>1. Respirators (FFP2 and FFP3)</p>
<p>2. Aprons </p>
<p>3. Protective overalls </p>
<p>4. Protective eyewear </p>
<p>5. Disposable caps</p>
</div></section><section id="annex_4/lvl_u1/lvl_3/lvl_3_2"><h4 class="heading" role="heading" aria-level="4">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_4/lvl_u1/lvl_3/lvl_3_2">3.2  Further equipment</a>
</h4>
<div class="collapseable"> <p>1. Hand disinfectants </p>
<p>2. Surface disinfectants </p>
<p>3. Ethanol</p>
<p>4. Hygiene products for intensive care (such as absorbent pads, diapers, faecal collectors, oral hygiene items)</p>
</div></section>
</div></section>
</div></section>
</div></section><section id="annex_5"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_5">Annex 5</a><sup><a href="#fn-d6e2415" id="fnbck-d6e2415">110</a></sup>
</h1>
<div class="footnotes"><p id="fn-d6e2415"><sup><a href="#fnbck-d6e2415">110</a></sup> Amended by No I para. 2 of the FDHA O of 23 March 2022 (Amendment of the List of important medical products and list of active substances for the treatment of COVID-19), (<a href="https://fedlex.data.admin.ch/eli/oc/2022/186" target="_blank">AS <b>2022</b> 186</a>). Revised by No II para. 1 of the O of 21 Dec. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div>
<div class="collapseable">
<p>(Art. 21 paras 1 and 3, as well as 22 para. 1)</p>
<section id="annex_5/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_5/lvl_u1">List of active substances for the treatment of COVID-19</a>
</h2>
<div class="collapseable"><dl>
<dt>1. </dt>
<dd>…</dd>
<dt>2. </dt>
<dd>Tixagevimab/Cilgavimab</dd>
</dl></div></section>
</div></section><section id="annex_5_a"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_5_a">Annex 5a</a><sup><a href="#fn-d6e2443" id="fnbck-d6e2443">111</a></sup>
</h1>
<div class="footnotes"><p id="fn-d6e2443"><sup><a href="#fnbck-d6e2443">111</a></sup> Inserted by No III para. 1 of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests) (<a href="https://fedlex.data.admin.ch/eli/oc/2020/977" target="_blank">AS <b>2020</b> 5801</a>). Amended by No II para. 2 of the O of 21. Dez. 2022, in force since 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div>
<div class="collapseable">
<p>(Art. 21 para. 1<sup>bis</sup> and 3)</p>
<section id="annex_5_a/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_5_a/lvl_u1">List of active substances that prevent COVID-19 infection</a>
</h2>
<div class="collapseable"><p>There are no entries currently on this list.</p></div></section>
</div></section><section id="annex_6"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_6">Annex 6</a><sup><a href="#fn-d6e2468" id="fnbck-d6e2468">112</a></sup>
</h1>
<div class="footnotes"><p id="fn-d6e2468"><sup><a href="#fnbck-d6e2468">112</a></sup> Inserted by No II of the O of 28 Oct. 2020 (Sars-CoV-2 Rapid Antigen Tests)  (<a href="https://fedlex.data.admin.ch/eli/oc/2020/792" target="_blank">AS <b>2020</b> 4495</a>). Repealed by No II para. 3 of the O of 21 Dec. 2022, with effect from 1 Jan. 2023 (<a href="https://fedlex.data.admin.ch/eli/oc/2022/838" target="_blank">AS <b>2022</b> 838</a>).</p></div>
<div class="collapseable"></div></section><section id="annex_7"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_7">Annex 7</a><sup><a href="#fn-d6e2485" id="fnbck-d6e2485">113</a></sup>
</h1>
<div class="footnotes"><p id="fn-d6e2485"><sup><a href="#fnbck-d6e2485">113</a></sup> Inserted by No II of the O of 13 Jan. 2021 (Employees at High Risk), in force from  18 Jan. 2021 to 31 Dec. 2021 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/5" target="_blank">AS <b>2021</b> 5</a>). Amended by No II para. 1 of the O of  17 Dec. 2021, in force from 1 Jan. 2022 to 31 March 2022 (<a href="https://fedlex.data.admin.ch/eli/oc/2021/881" target="_blank">AS <b>2021</b> 881</a>; Art. 29 para. 7).</p></div>
<div class="collapseable"><p></p></div></section>
</div>
</div></body>
</html>
